Gf Fund Management Co. Ltd. Crinetics Pharmaceuticals, Inc. Transaction History
Gf Fund Management Co. Ltd.
- $4.26 Trillion
- Q1 2025
A detailed history of Gf Fund Management Co. Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 2,375 shares of CRNX stock, worth $71,630. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,375
Previous 1,947
21.98%
Holding current value
$71,630
Previous $99.6 Million
19.98%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
235Shares Held
87MCall Options Held
40KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA9.31MShares$281 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$208 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$188 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$188 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$154 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.62B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...